

## Cirrhosis in over 16s: assessment and management

### Advisory Committee Interests Register

Register last updated: 30.03.22

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Caroline Jones	Chair	Direct financial interest	Employed as Service Manager for School Nursing (part time) in Cornwall	November 2022	November 2022		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Caroline Jones	Chair	Direct financial interest	Senior Advisor Compliance and Quality, Specialist division, CareTech.  Providing advice on all issues relating to Quality improvement and compliance for regulators.  This role provides advice to Mental Health, Learning disabilities and autism hospital services.	November 2022	November 2022		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Caroline Jones	Chair	Direct financial interest	Chair - Nursing and Midwifery Council (NMC) Fitness to Practice Panels	October 2022	November 2022		Non- specific

			– Chair or Registrant member				No action needed other than process of open declaration  Agreed by: Guideline Lead, March 2023
Alastair O'Brien	Committee member  Topic Adviser – Hepatologist	Direct financial interest	Undertakes hepatology private practice at The Cleveland Clinic London. Private practice accounts for approx. 15% of overall practice and mirrors NHS practice.	September 2021	August 2022		Interest is specific but accounts for only approx. 15% of clinical work and open declaration is sufficient mitigation.  Agreed by: Guideline Lead, March 2023
Alastair O'Brien	Committee member  Topic Adviser – Hepatologist	Direct financial interest	Speaking engagement with Mallinckrodt Pharmaceuticals. Honorarium received.	June 2022	August 2022	June 2022	Specific  No action needed other than process of open declaration (non-promotional one-off event)  Agreed by: Guideline Lead, March 2023
Alastair O'Brien	Committee member  Topic Adviser – Hepatologist	Direct financial interest	Speaking engagement with CSL Behring. Honorarium received.	February 2022	August 2022	February 2022	Specific  No action needed other than process of open declaration (non-promotional one-off event)

							Agreed by: Guideline Lead, March 2023
Alastair O'Brien	Committee member Topic Adviser – Hepatologist	Direct financial interest	Speaking engagement with Novartis. Honorarium received.	April 2018	August 2022	April 2018	Specific No action needed other than process of open declaration (non-promotional one-off event) Agreed by: Guideline Lead, March 2023
Alastair O'Brien	Committee member Topic Adviser – Hepatologist	Non-financial professional and personal interest	CI for is ASEPTIC - Primary Antibiotic prophylaxis using co-trimoxazole to prevent Spontaneous bacterial Peritonitis in Cirrhosis Funding: NIHR Health Technology Assessment	January 2020	September 2022	Ongoing, due to end 2024.	Specific No action needed other than process of open declaration The ASEPTIC trial is ongoing and will not report during the lifetime of this update. Agreed by: Guideline Lead, March 2023
Alastair O'Brien	Committee member Topic Adviser – Hepatologist	Direct financial interest	Consultant Hepatologist, The Royal Free & University College Hospitals London	October 2007	August 2022		Declare and participate – salaried employment in the NHS Agreed by: Guideline Lead, March 2023

Andrew Fowell	Committee member Hepatologist	Direct financial interest	Paid endoscopy work for Practice Plus Group, an Independent Sector NHS provider. Private practice accounts for approx. 5-10% of overall practice and mirrors NHS practice.	2012	November 2022		Interest is specific but accounts for only approx. 5-10% of clinical work and open declaration is sufficient mitigation.  Agreed by: Guideline Lead, March 2023
Andrew Fowell	Committee member Hepatologist	Non-financial professional and personal interest	Royal College of Physicians Regional Advisor for Gastroenterology and Hepatology (Wessex)	June 2020	November 2020		Non- specific No action needed other than process of open declaration  Agreed by: Guideline Lead, March 2023
Andrew Fowell	Committee member Hepatologist	Non-financial professional and personal interest	British Society of Gastroenterology Regional representative (Wessex)	June 2020	November 2020		Non- specific No action needed other than process of open declaration  Agreed by: Guideline Lead, March 2023
Andrew Fowell	Committee member Hepatologist	Direct financial interest	Consultant Hepatologist & Gastroenterologist, Portsmouth Hospitals University NHS Trust	August 2011	October 2022		Declare and participate – salaried employment in the NHS  Agreed by: Guideline Lead, March 2023

Andrew Fowell	Committee member Hepatologist	Direct financial interest	Advisory board member for Dr Falk Pharma UK Ltd. Honorarium plus travel expenses to be received: Attendance at January 2023 meeting concerning autoimmune hepatitis.	January 2023	January 2023		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Vanessa Hebditch	Committee member Lay member	Non-financial professional and personal interest	Works for the British Liver Trust. Personally, has no conflicts of interest (either financial or otherwise). However, the British Liver Trust does receive grants from pharmaceutical companies. The Trust has very strict rules regarding these grants and all grants are arm's length; are given for British Liver Trust activities with no company being allowed to have any input into content etc.		January 2023		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Direct financial interest	Works for a research company (Panthera) as Principal Investigator for one site (Glasgow) in an advisory capacity with regards to their liver disease research (on fatty liver	January 2021	November 2022		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023

Mathis Heydtmann	Committee member Hepatologist	Direct financial interest	Has a private practice (at BMI Ross Hall and Nuffield Health Glasgow) seeing patients with liver disease (pre-cirrhotic and cirrhotic). Private practice accounts for approx. 20% of overall practice and is similar to NHS practice.	2010	November 2022		Interest is specific but accounts for only approx. 20% of clinical work and open declaration is sufficient mitigation.  Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	Is a specialist advisor to the Scottish Chief Medical Officer for liver disease.	2017	November 2022		Non- specific  No action needed other than process of open declaration  Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	Represents Scotland in the UK Liver Alliance (following on from the Lancet Liver Alliance)	2019	November 2022		Non- specific  No action needed other than process of open declaration  Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	Works with the British Liver Trust to advocate for increased awareness of the often deprived and underserved people with liver disease. This is to influence politicians and policy makers to make	2019	November 2022		Non- specific  No action needed other than process of open declaration  Agreed by: Guideline Lead, March 2023

			evidence based decisions and decrease health inequities.				
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	Is a member of Scottish Health Action on the Alcohol Problem (SHAAP) and Vice Chair of SHAAP since 2020.	2014	November 2022		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	Is part of a European Network (LiverScreen) investigating biomarkers and liver stiffness measurements to detect liver disease early in high risk groups		November 2022		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	In role as Principal Investigator is involved in trials investigating the progression of fibrosis		November 2022		Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Non-financial professional and personal interest	Is a member of the Scottish Society of Gastroenterology Council and was secretary of the Society from 2018 to 2021.	2007	November 2022	2021	Non- specific No action needed other than process of open declaration

							Agreed by: Guideline Lead, March 2023
Mathis Heydtmann	Committee member Hepatologist	Direct financial interest	Consultant Hepatologist in Dumfries and Galloway Royal Infirmary		October 2022		Declare and participate – salaried employment in the NHS  Agreed by: Guideline Lead, March 2023
Kathryn Jack	Committee member Specialist nurse	Direct financial interest	Surgery Division Lead Nurse for Research and Innovation & Institute of Care Excellence Clinical Lead for Research and Innovation, Nottingham University Hospitals NHS Trust	September 2022	November 2022		Declare and participate – salaried employment in the NHS  Agreed by: Guideline Lead, March 2023
Fatema Jessa	Committee member Pharmacist	Direct financial interest	Currently employed by Royal Free London NHS Foundation Trust as Consultant Pharmacist (progressive post) in Hepatology and Liver Transplant managing patients with cirrhosis	September 2022	November 2022		Declare and participate – salaried employment in the NHS  Agreed by: Guideline Lead, March 2023



Fatema Jessa	Committee member Pharmacist	Non-financial professional and personal interest	Co-authored CPD article in Pharmaceutical Journal – <a href="#">Medicines management in adult patients undergoing liver transplantation</a> contains section on patients with cirrhosis.	March 2021	November 2022	December 2021	Non- specific No action needed other than process of open declaration Agreed by: Guideline Lead, March 2023
Fatema Jessa	Committee member Pharmacist	Direct financial interest	Invited to present an educational event on at the end of April 2023 on behalf of Advanz Pharma on Primary Biliary Cirrhosis and will receive an honorarium. The talk is on setting up a pharmacist led PBC clinic.	April 2023	March 2023		Specific No action needed other than process of open declaration (non-promotional one-off event and Advanz Pharma are unlikely to benefit from the guideline update) Agreed by: Guideline Lead, March 2023
Imaad Rafiq	Committee member Lay member	Nil	Nil				Nil

Emmanuel Wey	Committee member Microbiologist	Non-financial professional and personal interest	Member on the advisory board panel for CloverBiosoft. Advisory capacity for AI software company and involved in the development of Infection related applications used in clinical and RUO diagnostics. Speaker at research conferences and meetings	August 2018	November 2022		Non-specific No action needed other than process of open declaration EQ advises on diagnostics directed towards the detection of antimicrobial resistance. CloverBiosoft should not directly benefit from the guideline update. Agreed by: Guideline Lead, March 2023
Emmanuel Wey	Committee member Microbiologist	Direct financial interest	Consultant in Infection, Royal Free London NHS Foundation Trust	2015	August 2022		Declare and participate – salaried employment in the NHS Agreed by: Guideline Lead, March 2023

Emmanuel Wey	Committee member Microbiologist	Direct financial interest	Private Clinical work in the capacity as a Consultant in Infection for HCA hospitals, the Cleveland clinic and The Doctors laboratory (TDL). Private practice accounts for approx. 10% of overall practice and mirrors NHS practice.	June 2016	March 2023		Interest is specific but accounts for only approx. 10% of clinical work and open declaration is sufficient mitigation.  Agreed by: Guideline Lead, March 2023
--------------	------------------------------------	---------------------------	--	-----------	------------	--	---

**GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.